Peptides Lab Ireland research team · Research article · Updated October 2026
An overview of retatrutide for laboratories in Northern Ireland, covering its mechanism and the published literature.
What retatrutide is
Retatrutide (LY3437943) is a synthetic, fatty-acid-modified peptide that activates three receptors: GLP-1, GIP and glucagon. It is an investigational compound with no marketing authorisation as a medicine.
How it works at the receptor level
All three receptors signal mainly through Gs and cAMP. GLP-1 and GIP receptors are studied for their roles in glucose-dependent insulin secretion and satiety signalling. The glucagon receptor is studied for its effects on liver metabolism and energy expenditure. Researchers use retatrutide to compare a three-receptor molecule with single (semaglutide) and dual (tirzepatide) agonists.
Key published research
- Discovery and preclinical pharmacology, including receptor potency and early pharmacokinetics: Coskun et al., Cell Metab 2022, PMID 35985340.
- Phase 2 randomised, double-blind, placebo-controlled trial: Jastreboff et al., N Engl J Med 2023, PMID 37366315.
Protocols used in published studies
The table below describes what the Phase 2 trial investigators did. It is a summary of the published study design, not a recommendation, and these protocols must not be applied outside an approved clinical trial.
| Study | Study design |
|---|---|
| Retatrutide Phase 2 (PMID 37366315) | 338 adults randomised to placebo or one of several retatrutide arms, followed for 48 weeks |
Regulatory context
Northern Ireland follows UK medicines regulation (MHRA). Retatrutide is investigational and has no marketing authorisation.
Storage and handling in the laboratory
- Store lyophilised material at −20 °C, protected from light and moisture.
- Keep reconstituted solutions at 2–8 °C and label them with compound, concentration and date.
- Aliquot stock solutions to avoid repeated freeze/thaw cycles.
- Use low-binding tubes and tips for dilute solutions, as acylated peptides can stick to plastics.
Related research articles
- Retatrutide research overview
- Tirzepatide research overview
- GLP-1, dual and triple agonists compared
- Peptide cold-chain storage
For laboratory research use only. This article summarises published research for information. It is not medical advice and is not a guide to administration or treatment. The compounds discussed are not intended for human or veterinary use.